Adendra Therapeutics wants to use new insights into dendritic cell biology to develop a novel type of immunotherapy.
Adendra Therapeutics has raised $53.0M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Adendra Therapeutics's investors include Apple Tree Partners.
Adendra Therapeutics is headquartered in London, United Kingdom.
Adendra Therapeutics wants to use new insights into dendritic cell biology to develop a novel type of immunotherapy.
Adendra Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Adendra Therapeutics — Funding & Investors." VCBacked, December 7, 2021, https://www.vcbacked.co/company/adendra-therapeutics. Accessed November 14, 2026.
VCBacked. (2021). Adendra Therapeutics — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/adendra-therapeutics
{{cite web |title=Adendra Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/adendra-therapeutics |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Adendra Therapeutics? Request a listing update